<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200405046951N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-28</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of nutritional support on the recovery of patients admitted to the intensive care unit</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of nutritional support provided by a nutritionist in improving the outcomes of patients admitted to the intensive care unit (ICU)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66980</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use the limited randomization method of the block randomization type.
The randomization tool is also used from random sequence generation software (https://www.graphpad.com/quickcalcs/), which, in addition to simple randomization, is capable of generating random sequence by block method (10 blocks of 10). For concealment, we use random allocation concealment, which refers to the method used to perform a random sequence on study participants, in such a way that the allocated group is not known before individual allocation. By using sealed opaque letter envelopes with a random sequence, in this method, each of the random sequences created is recorded on a card and the cards are placed inside the letter envelopes in order. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of starting the registration of participants, based on the order in which eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Critically ill patient.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients admitted to the intensive care unit are under nutritional support including enteral or intravenous nutrition by a nutritionist. Enteral feeding will be done with gavage powders from Karen company, parentral feeding will be done with intralipid and amino acid solutions from Fresenius Kaby, and the amount to be consumed will be determined based on the patient's weight and other conditions. Intervention 2: Control group: patients hospitalized in the intensive care unit who will receive nutritional support including enteral or intravenous nutrition from other medical services (surgeon, internist, etc.).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Azadeh Mottaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.10, Firoozeh alley, Vali Asr Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15937</zip>
        <telephone>0098218608060</telephone>
        <email>mottaghi.azadeh@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Aazdeh Mottaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.10, Firoozeh Alley. Vali Asr Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593716615</zip>
        <telephone>+98 21 86701</telephone>
        <email>mottaghi.azadeh@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Hospitalization period of more than 3 days in the intensive care unit</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with extensive head trauma (GCS less than 8)
Severe liver disease (score C for Child Pugh)
Treated with dialysis
Patients who are admitted to the ICU for open-heart surgery are not included in the study because the duration of their hospitalization depends on several underlying factors.
Pregnancy
Patients who have not received nutritional support 48 hours after being admitted to the ICU for some reason will not be included in the plan</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients admitted to the intensive care unit are under nutritional support including enteral or intravenous nutrition by a nutritionist. Enteral feeding will be done with gavage powders from Karen company, parentral feeding will be done with intralipid and amino acid solutions from Fresenius Kaby, and the amount to be consumed will be determined based on the patient's weight and other conditions.</i_keyword>
      <i_keyword>Control group: patients hospitalized in the intensive care unit who will receive nutritional support including enteral or intravenous nutrition from other medical services (surgeon, internist, etc.).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Length of stay in ICU. Timepoint: before the intervention and when the patient is discharged from the intensive care unit. Method of measurement: Counting days of hospitalization.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of ventilator use or need. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Counting days of intervention (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>Mortality rate. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration  (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>Occurring new pressure ulcers. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration  (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>The need for surgery or unplanned medical interventions. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>Occurrence of kidney disorders with the definition of creatinine more than 1.2 mg/dL or the need for dialysis. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>The occurrence of liver disorders with the definition of bilirubin more than 1.2 mg/dL. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration (Event Registration Questionnaire).</sec_outcome>
      <sec_outcome>Incidence of infectious complications according to the definition of infection in the ICU of the International Sepsis Association (ventilator-associated pneumonia, bacteremia, urinary tract infections, wound infections, abdominal infections) 48 hours after the start of the intervention. Timepoint: During the intervention period (the duration of the patient's hospitalization in the intensive care unit). Method of measurement: Event registration (Event Registration Questionnaire).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-09</approval_date>
        <contact_name>Research Ethics Committees of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
